Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “the First Line Treatment”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01788982
What this trial is testing

Nintedanib(BIBF1120) in Thyroid Cancer

Who this might be right for
Medullary Thyroid Cancer (MTC)Differentiated Thyroid Cancer (DTC)
European Organisation for Research and Treatment of Cancer - EORTC 100
Testing effectiveness (Phase 2)Study completedNCT00719550
What this trial is testing

AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer

Who this might be right for
Esophagogastric Junction AdenocarcinomaGastric CancerEsophageal Cancer
Amgen 130
Large-scale testing (Phase 3)Study completedNCT00047255
What this trial is testing

Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer

Who this might be right for
Breast Cancer
Jonsson Comprehensive Cancer Center 263
Large-scale testing (Phase 3)Looking for participantsNCT07584135
What this trial is testing

JS107 in Combination With Toripalimab and Chemotherapy for the Treatment of CLDN18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric Adenocarcinoma
NingBo Junyan Hongshi Biosciences Co., Ltd 600
Not applicableNot Yet RecruitingNCT06998290
What this trial is testing

Feasibility of Home Telemonitoring of Infants With Congenital Heart Disease Awaiting Surgery During the First Year of Life

Who this might be right for
CHD - Congenital Heart Disease
University Hospital, Bordeaux 20
Testing effectiveness (Phase 2)Study completedNCT00191490
What this trial is testing

Study Evaluating the Feasibility and Activity of Three Different Combination With Gemcitabine as First Line Therapy for Non Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Eli Lilly and Company 162
Large-scale testing (Phase 3)Study completedNCT01709084
What this trial is testing

A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment

Who this might be right for
Human Immunodeficiency Virus-type 1 Infection
Janssen-Cilag International NV 426
Not applicableEnded earlyNCT02949908
What this trial is testing

MEasuring Satisfaction of Treatment With REbif After Initial Treatment of Multiple Sclerosis (MS)

Who this might be right for
Multiple Sclerosis
Merck KGaA, Darmstadt, Germany 2
Testing effectiveness (Phase 2)Study completedNCT04834674
What this trial is testing

DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma

Who this might be right for
Intrahepatic CholangiocarcinomaTransarterial ChemoembolizationApatinib+1 more
Sichuan Cancer Hospital and Research Institute 20
Large-scale testing (Phase 3)Not Yet RecruitingNCT06841185
What this trial is testing

Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma (HCC)
Shanghai Henlius Biotech 656
Large-scale testing (Phase 3)Study completedNCT03430297
What this trial is testing

A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma

Who this might be right for
Metastatic MelanomaUnresectable Melanoma
Shanghai Junshi Bioscience Co., Ltd. 256
Testing effectiveness (Phase 2)UnknownNCT04191343
What this trial is testing

Clinical Study on the First-line Treatment of Advanced Biliary System Tumors With Tripley Monoclonal Antibody Combined With GEMOX Regimen

Who this might be right for
Advanced Biliary Tract Tumors
Zhejiang Cancer Hospital 20
Large-scale testing (Phase 3)Study completedNCT03713593
What this trial is testing

Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)

Who this might be right for
Carcinoma, Hepatocellular
Merck Sharp & Dohme LLC 794
Testing effectiveness (Phase 2)Study completedNCT00518011
What this trial is testing

Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 17
Testing effectiveness (Phase 2)UnknownNCT04211012
What this trial is testing

A Study on Toripalimab Plus Nab-Paclitaxel With or Without Cisplatin as First-line Treatment of Urothelial Carcinoma

Who this might be right for
Urothelial Carcinoma
Jun Guo 30
Large-scale testing (Phase 3)Study completedNCT01160211
What this trial is testing

Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

Who this might be right for
Neoplasms, Breast
Novartis Pharmaceuticals 369
Testing effectiveness (Phase 2)Active Not RecruitingNCT04284787
What this trial is testing

BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia Post Cytotoxic Therapy+1 more
National Cancer Institute (NCI)
Not applicableLooking for participantsNCT07096258
What this trial is testing

EMPATHY NSCLC: European Registry for Plasma-Based Molecular Profiling in Advanced NSCLC Patients

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)
Hedera Dx SA 1,000
Large-scale testing (Phase 3)Active Not RecruitingNCT06212752
What this trial is testing

Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension

Who this might be right for
Metastatic Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC 39
Testing effectiveness (Phase 2)Looking for participantsNCT07209059
What this trial is testing

PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma

Who this might be right for
Hodgkin LymphomaHodgkin DiseaseAdvanced Hodgkin Lymphoma
National Research Center for Hematology, Russia 30
Next Page
60